Credit Suisse AG Grows Stock Holdings in Dynavax Technologies Co. (NASDAQ:DVAX)

Credit Suisse AG lifted its position in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 4.6% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 191,071 shares of the biopharmaceutical company’s stock after buying an additional 8,366 shares during the quarter. Credit Suisse AG owned approximately 0.15% of Dynavax Technologies worth $1,874,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of DVAX. State Street Corp lifted its stake in shares of Dynavax Technologies by 36.1% during the 1st quarter. State Street Corp now owns 8,498,732 shares of the biopharmaceutical company’s stock valued at $92,126,000 after buying an additional 2,253,376 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Dynavax Technologies by 138.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,791,380 shares of the biopharmaceutical company’s stock valued at $19,060,000 after buying an additional 1,040,404 shares in the last quarter. Mizuho Markets Cayman LP purchased a new stake in Dynavax Technologies in the 1st quarter worth $7,425,000. BNP Paribas Arbitrage SNC lifted its stake in Dynavax Technologies by 2,036.1% in the 3rd quarter. BNP Paribas Arbitrage SNC now owns 665,636 shares of the biopharmaceutical company’s stock worth $6,949,000 after purchasing an additional 634,475 shares in the last quarter. Finally, Morgan Stanley lifted its stake in Dynavax Technologies by 44.5% in the 4th quarter. Morgan Stanley now owns 2,040,718 shares of the biopharmaceutical company’s stock worth $21,713,000 after purchasing an additional 628,657 shares in the last quarter. Hedge funds and other institutional investors own 99.13% of the company’s stock.

Dynavax Technologies Stock Performance

Dynavax Technologies stock opened at $14.54 on Tuesday. The company’s 50-day moving average price is $14.03 and its 200-day moving average price is $11.99. Dynavax Technologies Co. has a twelve month low of $9.42 and a twelve month high of $15.12. The company has a quick ratio of 16.59, a current ratio of 17.78 and a debt-to-equity ratio of 0.38. The company has a market cap of $1.87 billion, a PE ratio of 20.19 and a beta of 1.52.

Dynavax Technologies (NASDAQ:DVAX) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $0.03 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.12. Dynavax Technologies had a net margin of 24.08% and a return on equity of 19.91%. The firm had revenue of $60.25 million for the quarter, compared to the consensus estimate of $51.03 million. On average, equities research analysts forecast that Dynavax Technologies Co. will post -0.24 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have commented on DVAX. StockNews.com began coverage on shares of Dynavax Technologies in a research note on Thursday, August 17th. They issued a “hold” rating on the stock. JMP Securities boosted their price target on shares of Dynavax Technologies from $24.00 to $25.00 and gave the stock an “outperform” rating in a research note on Friday, August 4th. Finally, HC Wainwright reiterated a “buy” rating and issued a $27.00 price target on shares of Dynavax Technologies in a research note on Friday, August 4th.

Insider Activity at Dynavax Technologies

In related news, Director Andrew A. F. Hack sold 500,000 shares of the company’s stock in a transaction dated Wednesday, June 14th. The shares were sold at an average price of $12.68, for a total transaction of $6,340,000.00. Following the transaction, the director now directly owns 2,415,000 shares in the company, valued at approximately $30,622,200. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Andrew A. F. Hack sold 500,000 shares of the company’s stock in a transaction dated Wednesday, June 14th. The shares were sold at an average price of $12.68, for a total transaction of $6,340,000.00. Following the transaction, the director now directly owns 2,415,000 shares in the company, valued at approximately $30,622,200. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Andrew A. F. Hack sold 1,500,000 shares of the company’s stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $14.39, for a total transaction of $21,585,000.00. Following the completion of the transaction, the director now owns 915,000 shares in the company, valued at $13,166,850. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 2,085,518 shares of company stock worth $29,199,341. Insiders own 9.31% of the company’s stock.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.